Loading…
Loading…
Sentiment · FY2026 Q1
| Analyst | Firm | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| Salveen Richter | Goldman Sachs | 6 | 17% |
| Brian Abrahams | RBC Capital Markets | 6 | 0% |
| Evan Seigerman | BMO Capital Markets | 5 | 0% |
| Mike Yee | UBS | 5 | 0% |
| Umer Raffat | Evercore ISI | 4 | 0% |
| Terence Flynn | Morgan Stanley | 3 | 0% |
| Dave Amsellem | Piper Sandler | 3 | 33% |
| Phil Nadeau | TD Cowen | 3 | 33% |
| Paul Matteis | Stifel | 3 | 33% |
| Jay Olson | Oppenheimer | 3 | 0% |
| Firm | Analysts | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| Goldman Sachs | 1 | 6 | 17% |
| RBC Capital Markets | 1 | 6 | 0% |
| UBS | 1 | 5 | 0% |
| Evercore ISI | 2 |
| 5 |
| 0% |
| BMO Capital Markets | 1 | 5 | 0% |
| Stifel | 2 | 4 | 25% |
| Morgan Stanley | 1 | 3 | 0% |
| Oppenheimer | 1 | 3 | 0% |
Biogen started FY2026 with revenue up 1.9% as growth products generated $851 million, now exceeding MS revenue for the first time. LEQEMBI market revenue reached $168 million up 74% year-over-year, and SPINRAZA High Dose was approved with strong early uptake. The Apellis acquisition added portfolio breadth but increased leverage. Operating income declined on higher investment spending, and FY2026 EPS guidance of $15.25-$16.25 was maintained as the business outlook confirmed tracking toward the upper end.
Innovation & R&D | Competitive Dynamics | Product Launch | Demand | M&A | Capital Allocation | Revenue Growth | Geographic Expansion | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | |
| 2025Q1 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 1 |
| 2025Q2 | 5 | 5 | 2 | 5 | 1 | 1 | 1 | |
| 2025Q3 | 5 | 2 | 4 | 2 | 2 | 2 | 1 | |
| 2025Q4 | 5 | 3 | 4 | 2 | 2 | 2 | 2 | 1 |
| 2026Q1 | 4 | 4 | 4 | 5 | 3 | 2 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Innovation & R&D | 2 | 3 | 5 | 5 | 5 | 4 |
| Competitive Dynamics | 3 | 3 | 5 | 2 | 3 | 4 |
| Product Launch | 3 | 3 | 2 | 4 | 4 | 4 |
| Demand | 2 | 2 | 5 | 2 | 2 | 5 |
| M&A | 2 | 1 | 1 | 2 | 2 | 3 |
| Capital Allocation | 2 | 1 | 1 | 2 | 2 | 2 |
| Revenue Growth | 2 | 1 | 1 | 2 | ||
| Geographic Expansion | 1 | 1 | 1 | 1 |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
BIIB Biogen | 4 | +1.9% | |
| ABBV AbbVie | 9 | +12.4% | |
| AMGN Amgen Inc. | 8 | +5.8% | |
| BMY Bristol Myers Squibb | 4 | +2.6% | |
| GILD Gilead Sciences | 8 | +4.4% | |
| JNJ Johnson & Johnson | 7 | +10.1% | |
| LLY Lilly (Eli) | 10 | +55.5% | |
| MRK Merck & Co., Inc. | 7 | +4.3% | |
| PFE Pfizer | 5 | +5.4% |